Cellectis' gene edited CAR T-cells: how does it work?

InfoWeb Marketplace

mercredi 21 septembre 2016Description
Cellectis is a preclinical stage biopharmaceutical company focused on developing immunotherapies based on gene edited engineered CAR-T cells (UCART). The company's mission is to develop a new generation of cancer therapies based on engineered T-cells. Cellectis capitalizes on its 15 years of expertise in genome engineering - based on its flagship TALEN® products and meganucleases and pioneering electroporation PulseAgile technology - to create a new generation of immunotherapies. CAR technologies are designed to target surface antigens expressed on cells.

Recherches associées à Biotechnologie blanche

Devis groupés (0)